{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:52:43Z","timestamp":1792806763591,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe chronic hyperglycaemia (\u2009&gt;\u200915\u2009mM) causes impaired glycolytic and mitochondrial metabolism in pancreatic \u03b2-cells, leading to dramatically reduced insulin secretion and content. However, patients with type 2 diabetes often experience many years of reduced \u03b2-cell function and impaired glucose tolerance preceding diabetes diagnosis. It is postulated that \u03b2-cell function may be compromised by relatively small changes in glycaemia, initiating a gradual decline that underlies diabetes progression. We therefore investigated the extent to which impaired glucose tolerance and chronic mild hyperglycaemia are detrimental to \u03b2-cells. We show that chronic elevation of blood glucose of just 2-3\u2009mM is sufficient to impair \u03b2-cell function, causing marked changes in metabolic gene expression and reducing insulin content, metabolic enzyme activity, mitochondrial oxidative phosphorylation and insulin secretion. Smaller but significant changes are produced by impaired glucose tolerance. These findings demonstrate that altered \u03b2-cell metabolism is an early event in type 2 diabetes development and highlight a need for therapeutic intervention during prediabetes.<\/jats:p>","DOI":"10.1038\/s41467-026-71528-3","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:43:10Z","timestamp":1777563790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impaired glucose tolerance and mild diabetes induce \u03b2-cell dysfunction in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-9240","authenticated-orcid":false,"given":"Elizabeth","family":"Haythorne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-6125","authenticated-orcid":false,"given":"Martijn","family":"van de Bunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3926-1534","authenticated-orcid":false,"given":"Maria","family":"Rohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0062-6137","authenticated-orcid":false,"given":"Alice","family":"Elphick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Cyranka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4232-2898","authenticated-orcid":false,"given":"Fiona M.","family":"Gribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-6377","authenticated-orcid":false,"given":"Frank","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-1767","authenticated-orcid":false,"given":"Frances M.","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"71528_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD21 Diabetes collaborators","year":"2023","unstructured":"GBD21 Diabetes collaborators Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"71528_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","volume":"44","author":"UK Prospective Diabetes Study Group","year":"1995","unstructured":"UK Prospective Diabetes Study Group UK Prospective Diabetes Study 16: overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. Diabetes 44, 1249\u20131258 (1995).","journal-title":"Diabetes"},{"key":"71528_CR3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1074\/mcp.M700478-MCP200","volume":"7","author":"H Lu","year":"2008","unstructured":"Lu, H., Yang, Y., Allister, E. M., Wijesekara, N. & Wheeler, M. B. The identification of potential factors associated with the development of type 2 diabetes. Mol. Cell. Proteom. 7, 1434\u20131451 (2008).","journal-title":"Mol. Cell. Proteom."},{"key":"71528_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.2337\/db09-0129","volume":"59","author":"H Lu","year":"2010","unstructured":"Lu, H., Koshkin, V., Allister, E. M., Gyulkhandanyan, A. V. & Wheeler, M. B. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes 59, 448\u2013459 (2010).","journal-title":"Diabetes"},{"key":"71528_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13496","volume":"7","author":"MF Brereton","year":"2016","unstructured":"Brereton, M. F. et al. Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic beta-cells. Nat. Commun. 7, 13496 (2016).","journal-title":"Nat. Commun."},{"key":"71528_CR6","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2337\/db16-1305","volume":"66","author":"J Hou","year":"2017","unstructured":"Hou, J. et al. Temporal transcriptomic and proteomic landscapes of deteriorating pancreatic islets in type 2 diabetic rats. Diabetes 66, 2188\u20132200 (2017).","journal-title":"Diabetes"},{"key":"71528_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10189-x","volume":"10","author":"E Haythorne","year":"2019","unstructured":"Haythorne, E. et al. Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic \u03b2-cells. Nat. Commun. 10, 2474 (2019).","journal-title":"Nat. Commun."},{"key":"71528_CR8","doi-asserted-by":"publisher","first-page":"100959","DOI":"10.1016\/j.molmet.2020.02.002","volume":"35","author":"AG Ebrahimi","year":"2020","unstructured":"Ebrahimi, A. G. et al. Beta cell identity changes with mild hyperglycemia: implications for function, growth, and vulnerability. Mol. Metab. 35, 100959 (2020).","journal-title":"Mol. Metab."},{"key":"71528_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34095-x","volume":"13","author":"E Haythorne","year":"2022","unstructured":"Haythorne, E. et al. Altered glycolysis triggers impaired mitochondrial metabolism and mTORC1 activation in diabetic \u03b2-cells. Nat. Commun. 13, 6754 (2022).","journal-title":"Nat. Commun."},{"key":"71528_CR10","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1172\/JCI115989","volume":"90","author":"DL Eizirik","year":"1992","unstructured":"Eizirik, D. L., Korbutt, G. S. & Hellerstrom, C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J. Clin. Invest. 90, 1263\u20131268 (1992).","journal-title":"J. Clin. Invest."},{"key":"71528_CR11","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1007\/s00125-020-05275-5","volume":"63","author":"I Chareyon","year":"2020","unstructured":"Chareyon, I. et al. Augmented mitochondrial energy metabolism is an early response to chronic glucose stress in human pancreatic beta cells. Diabetologia 63, 2628\u20132640 (2020).","journal-title":"Diabetologia"},{"key":"71528_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/ijms22041813","volume":"22","author":"J Mir-Coll","year":"2021","unstructured":"Mir-Coll, J. et al. Human islet microtissues as an in vitro and an in vivo model system for diabetes. Int. J. Mol. Sci. 22, 1813\u20131836 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"71528_CR13","first-page":"5535","volume":"89","author":"P Marchetti","year":"2004","unstructured":"Marchetti, P. et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. Diabetologia 89, 5535\u20135541 (2004).","journal-title":"Diabetologia"},{"key":"71528_CR14","doi-asserted-by":"publisher","first-page":"e11499","DOI":"10.1371\/journal.pone.0011499","volume":"5","author":"L Marselli","year":"2010","unstructured":"Marselli, L. et al. Gene expression profiles of beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One 5, e11499 (2010).","journal-title":"PLoS One"},{"key":"71528_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00125-004-1627-9","volume":"48","author":"M Anello","year":"2005","unstructured":"Anello, M. et al. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 48, 282\u2013289 (2005).","journal-title":"Diabetologia"},{"key":"71528_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1530\/EJE-11-0282","volume":"165","author":"AH Olsson","year":"2011","unstructured":"Olsson, A. H. et al. Decreased expression of genes involved in oxidative phosphorylation in human pancreatic islets from patients with type 2 diabetes. Eur. J. Endocrinol. 165, 589\u2013595 (2011).","journal-title":"Eur. J. Endocrinol."},{"key":"71528_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cmet.2016.08.020","volume":"24","author":"A Segerstolpe","year":"2016","unstructured":"Segerstolpe, A. et al. Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab. 24, 593\u2013607 (2016).","journal-title":"Cell Metab."},{"key":"71528_CR18","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1074\/jbc.M113.507335","volume":"289","author":"I G\u00f6hring","year":"2014","unstructured":"G\u00f6hring, I. et al. Chronic high glucose and pyruvate levels differentially affect mitochondrial bioenergetics and fuel-stimulated insulin secretion from clonal INS-1 832\/13 cells. J. Biol. Chem. 289, 3786\u20133798 (2014).","journal-title":"J. Biol. Chem."},{"key":"71528_CR19","doi-asserted-by":"publisher","first-page":"E87","DOI":"10.1152\/ajpendo.00218.2011","volume":"302","author":"NM Doliba","year":"2012","unstructured":"Doliba, N. M. et al. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics. Am. J. Physiol. Endocrinol. Metab. 302, E87\u2013E102 (2012).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"71528_CR20","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1210\/endo.136.8.7628391","volume":"136","author":"YP Zhou","year":"1995","unstructured":"Zhou, Y. P., Ostenson, C. G., Ling, Z. C. & Grill, V. Deficiency of pyruvate dehydrogenase activity in pancreatic islets of diabetic GK rats. Endocrinology 136, 3546\u20133551 (1995).","journal-title":"Endocrinology"},{"key":"71528_CR21","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00125-010-2039-7","volume":"54","author":"RK Benninger","year":"2011","unstructured":"Benninger, R. K. et al. Defects in beta cell Ca2+ signalling, glucose metabolism and insulin secretion in a murine model of K(ATP) channel-induced neonatal diabetes mellitus. Diabetologia 54, 1087\u20131097 (2011).","journal-title":"Diabetologia"},{"key":"71528_CR22","doi-asserted-by":"publisher","first-page":"107623","DOI":"10.1016\/j.celrep.2020.107623","volume":"31","author":"JC Davis","year":"2020","unstructured":"Davis, J. C. et al. Glucose response by stem cell derived b cells in vitro is inhibited by a bottleneck in glycolysis. Cell Rep. 31, 107623 (2020).","journal-title":"Cell Rep."},{"key":"71528_CR23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41587-022-01219-z","volume":"40","author":"D Balboa","year":"2022","unstructured":"Balboa, D. et al. Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol. 40, 1042\u20131055 (2022).","journal-title":"Nat. Biotechnol."},{"key":"71528_CR24","first-page":"327","volume":"27","author":"WE Toreson","year":"1951","unstructured":"Toreson, W. E. Glycogen infiltration (so-called hydropic degeneration) in the pancreas in human and experimental diabetes mellitus. Am. J. Pathol. 27, 327\u2013347 (1951).","journal-title":"Am. J. Pathol."},{"key":"71528_CR25","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s00125-016-4092-3","volume":"59","author":"WJ Malaisse","year":"2016","unstructured":"Malaisse, W. J. Role of glycogen metabolism in pancreatic islet b cell function. Diabetologia 59, 2489\u20132491 (2016).","journal-title":"Diabetologia"},{"key":"71528_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cmet.2017.05.014","volume":"26","author":"FM Ashcroft","year":"2017","unstructured":"Ashcroft, F. M., Rohm, M., Clark, A. & Brereton, M. Is type 2 diabetes a glycogen storage disease of pancreatic beta-cells?. Cell Metab. 26, 17\u201323 (2017).","journal-title":"Cell Metab."},{"key":"71528_CR27","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.2337\/diabetes.53.suppl_3.S16","volume":"53","author":"GC Weir","year":"2004","unstructured":"Weir, G. C. & Bonner-Weir, S. Five stages of evolving \u03b2-cell dysfunction during progression to diabetes. Diabetes 53, S16\u2013S21 (2004).","journal-title":"Diabetes"},{"key":"71528_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2337\/dbi22-0030","volume":"72","author":"FM Ashcroft","year":"2023","unstructured":"Ashcroft, F. M. The Banting lecture 2022: KATP channels and the metabolic regulation of insulin secretion in health and disease. Diabetes 72, 693\u2013702 (2023).","journal-title":"Diabetes"},{"key":"71528_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5639","volume":"5","author":"MF Brereton","year":"2014","unstructured":"Brereton, M. F. et al. Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. Nat. Commun. 5, 4639 (2014).","journal-title":"Nat. Commun."},{"key":"71528_CR30","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/nm.3287","volume":"19","author":"G Xu","year":"2013","unstructured":"Xu, G., Chen, J., Jing, G. & Shalev, A. Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat. Med. 19, 1141\u20131146 (2013).","journal-title":"Nat. Med."},{"key":"71528_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cmet.2017.11.004","volume":"27","author":"A Ardestani","year":"2018","unstructured":"Ardestani, A., Lupse, B., Kido, Y., Leibowitz, G. & Maedler, K. mTORC1 signalling: a double-edged sword in diabetic \u03b2 cells. Cell Metab. 27, 314\u2013331 (2018).","journal-title":"Cell Metab."},{"key":"71528_CR32","doi-asserted-by":"publisher","first-page":"e4954","DOI":"10.1371\/journal.pone.0004954","volume":"4","author":"E Bachar","year":"2009","unstructured":"Bachar, E. et al. Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic beta-cells via activation of mTORC1. PLoS ONE 4, e4954 (2009).","journal-title":"PLoS ONE"},{"key":"71528_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00125-016-4188-9","volume":"60","author":"T Yuan","year":"2017","unstructured":"Yuan, T. et al. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes. Diabetologia 60, 668\u2013678 (2017).","journal-title":"Diabetologia"},{"key":"71528_CR34","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1172\/JCI127021","volume":"129","author":"R Jaafer","year":"2019","unstructured":"Jaafer, R. et al. (2019) mTORC1 to AMPK switching underlies \u03b2-cell metabolic plasticity during maturation and diabetes. J. Clin. Invest. 129, 4124\u20134137 (2019).","journal-title":"J. Clin. Invest."},{"key":"71528_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","volume":"39","author":"K Duvel","year":"2010","unstructured":"Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell. 39, 171\u2013183 (2010).","journal-title":"Mol. Cell."},{"key":"71528_CR36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00125-003-1169-6","volume":"46","author":"E Ferrannini","year":"2003","unstructured":"Ferrannini, E. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 46, 1211\u20131219 (2003).","journal-title":"Diabetologia"},{"key":"71528_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2337\/db11-0995","volume":"61","author":"M Kanat","year":"2012","unstructured":"Kanat, M. et al. Distinct \u03b2-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes 61, 447\u2013453 (2012).","journal-title":"Diabetes"},{"key":"71528_CR38","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1365-2265.2011.04205.x","volume":"76","author":"C Wang","year":"2012","unstructured":"Wang, C. et al. Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clin. Endocrinol. 76, 810\u2013815 (2012).","journal-title":"Clin. Endocrinol."},{"key":"71528_CR39","first-page":"80","volume":"119","author":"CA Girard","year":"2009","unstructured":"Girard, C. A. et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse beta-cells recapitulates neonatal diabetes. J. Clin. Investig. 119, 80\u201390 (2009).","journal-title":"J. Clin. Investig."},{"key":"71528_CR40","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s00125-016-3871-1","volume":"59","author":"J Mir-Coll","year":"2015","unstructured":"Mir-Coll, J. et al. Genetic models rule out a major role of beta cell glycogen in the control of glucose homeostasis. Diabetologia 59, 1012\u20131020 (2015).","journal-title":"Diabetologia"},{"key":"71528_CR41","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.metabol.2011.02.002","volume":"60","author":"C Ketterer","year":"2011","unstructured":"Ketterer, C. et al. Genetic variation within the TRPM5 locus associates with prediabetic phenotypes in subjects at increased risk for type 2 diabetes. Metabolism 60, 1325\u20131333 (2011).","journal-title":"Metabolism"},{"key":"71528_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/79216","volume":"26","author":"D Alshuler","year":"2000","unstructured":"Alshuler, D. et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26, 76\u201380 (2000).","journal-title":"Nat. Genet."},{"key":"71528_CR43","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1463-1326.2010.01299.x","volume":"12","author":"D Gupta","year":"2010","unstructured":"Gupta, D., Kono, T. & Evans-Molina, C. The role of peroxisome proliferator-activated receptor \u03b3 in pancreatic \u03b2 cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diab. Obes. Metab. 12, 1036\u20131047 (2010).","journal-title":"Diab. Obes. Metab."},{"key":"71528_CR44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4238\/vol9-2gmr802","volume":"9","author":"MAS Dehwah","year":"2010","unstructured":"Dehwah, M. A. S., Wnag, M. & Huang, Q.-Y. CDKLA1 and type 2 diabetes: a global meta-analysis. Genet. Mol. Res. 9, 1109\u20131120 (2010).","journal-title":"Genet. Mol. Res."},{"key":"71528_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/dom.12723","volume":"18","author":"D Acili","year":"2016","unstructured":"Acili, D. et al. When beta-cells fail: lessons from dedifferentiation. Diab. Obes. Metab. 18, 117\u2013122 (2016).","journal-title":"Diab. Obes. Metab."},{"key":"71528_CR46","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00125-007-0916-5","volume":"51","author":"C Ling","year":"2008","unstructured":"Ling, C. et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 51, 615\u2013622 (2008).","journal-title":"Diabetologia"},{"key":"71528_CR47","doi-asserted-by":"publisher","first-page":"e54106","DOI":"10.1371\/journal.pone.0054106","volume":"8","author":"R Spinnler","year":"2013","unstructured":"Spinnler, R. et al. The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion. PLoS ONE 8, e54106 (2013).","journal-title":"PLoS ONE"},{"key":"71528_CR48","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1016\/j.celrep.2017.08.093","volume":"20","author":"J Adam","year":"2017","unstructured":"Adam, J. et al. Fumarate hydratase deletion in pancreatic \u03b2 cells leads to progressive diabetes. Cell Rep. 20, 3135\u20133148 (2017).","journal-title":"Cell Rep."},{"key":"71528_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cmet.2013.05.018","volume":"18","author":"M Prentki","year":"2013","unstructured":"Prentki, M., Matschinsky, F. M. & Madiraju, S. R. Metabolic signaling in fuel induced insulin secretion. Cell Metab. 18, 162\u2013185 (2013).","journal-title":"Cell Metab."},{"key":"71528_CR50","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/brain\/awr104","volume":"134","author":"R Abeti","year":"2011","unstructured":"Abeti, R. et al. Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 134, 1658\u20131672 (2011).","journal-title":"Brain"},{"key":"71528_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s001250050090","volume":"37","author":"J Fernandez-Alvarez","year":"1994","unstructured":"Fernandez-Alvarez, J. et al. Enzymatic, metabolic and secretory patterns in human islets of type 2 (non-insulin-dependent) diabetic patients. Diabetologia 37, 177\u2013181 (1994).","journal-title":"Diabetologia"},{"key":"71528_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1042\/BJ20150269","volume":"472","author":"CA Droppelmann","year":"2015","unstructured":"Droppelmann, C. A. et al. A new level of regulation in gluconeogenesis: metabolic state modulates the intracellular localization of aldolase B and its interaction with liver fructose-1,6-bisphosphatase. Biochem. J. 472, 225\u2013237 (2015).","journal-title":"Biochem. J."},{"key":"71528_CR53","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1210\/jc.2018-00791","volume":"103","author":"F Gerst","year":"2018","unstructured":"Gerst, F. et al. The expression of aldolase b in islets is negatively associated with insulin secretion in humans. J. Clin. Endocrinol. Metab. 103, 4373\u20134383 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"71528_CR54","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s42255-021-00420-9","volume":"3","author":"L Wigger","year":"2021","unstructured":"Wigger, L. et al. Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories towards type 2 diabetes. Nat. Metab. 3, 1017\u20131031 (2021).","journal-title":"Nat. Metab."},{"key":"71528_CR55","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1172\/JCI81975","volume":"125","author":"M Shigeto","year":"2015","unstructured":"Shigeto, M. et al. GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. J. Clin. Invest 125, 4714\u20134728 (2015).","journal-title":"J. Clin. Invest"},{"key":"71528_CR56","first-page":"852","volume":"43","author":"A Fritsche","year":"2000","unstructured":"Fritsche, A., Stefan, N., Hardt, E., H\u00e4ring, H. & Stumvoll, M. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetes 43, 852\u2013858 (2000).","journal-title":"Diabetes"},{"key":"71528_CR57","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","volume":"52","author":"LL Kjems","year":"2003","unstructured":"Kjems, L. L., Holst, J. J., V\u00f8lund, A. & Madsbad, S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380\u2013386 (2003).","journal-title":"Diabetes"},{"key":"71528_CR58","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","volume":"404","author":"A Adler","year":"2024","unstructured":"Adler, A. et al. (2024) Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet 404, 145\u2013155 (2024).","journal-title":"Lancet"},{"key":"71528_CR59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tem.2022.12.007","volume":"34","author":"FM Ashcroft","year":"2023","unstructured":"Ashcroft, F. M., Lloyd, M. & Haythorne, E. Glucokinase activity in diabetes: too much of a good thing?. Trends Endocrinol. Metab. 34, 119\u2013130 (2023).","journal-title":"Trends Endocrinol. Metab."},{"key":"71528_CR60","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/db17-1195","volume":"67","author":"M Rohm","year":"2018","unstructured":"Rohm, M. et al. Cardiac dysfunction and metabolic inflexibility in a mouse model of diabetes without dyslipidemia. Diabetes 67, 1057\u20131067 (2018).","journal-title":"Diabetes"},{"key":"71528_CR61","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s42255-021-00440-5","volume":"3","author":"G Bidault","year":"2021","unstructured":"Bidault, G. et al. SREBP1-induced fatty acid synthesis depletes macrophages antioxidant defences to promote their alternative activation. Nat. Metab. 3, 1150\u20131162 (2021).","journal-title":"Nat. Metab."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71528-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71528-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71528-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:09:00Z","timestamp":1783386540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71528-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71528"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71528-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.vd.B. is a full-time employee of Cytoki Pharma, a clinical stage biotech company developing novel treatments for metabolic disease. The other authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5921"}}